‼️ #ASCO25 #JCOOA simultaneous publication by O'Neill et al:  Implementation of a Medication Reconciliation Televisit Model in Phase I Oncology Clinical Trials. Read the full article: brnw.ch/21wT6uo @pamelakunzmd.bsky.social

#ASCO25 #OncSky #crcsm NEW: Randomized trial of exercise vs health ed in people w/ #ColonCancer after adjuvant chemo: disease-free (HR 0.72; 6.4% abs diff at 5y) & overall (HR 0.63; 7.1% abs diff at 8y) survival improved w/ exercise! NNT ~14. ACTUALLY tolerable. 🏆 www.nejm.org/doi/full/10....

So grateful to have worked with this amazing group of friends and colleagues on #research priorities for #systemic therapies for #cholangiocarcinoma #biliarytractcancer #CCA #BTC @cholangiocarcinoma.bsky.social #HUNIMED #HUMANITAS @rachnatshroff.bsky.social @ardamanshergill.bsky.social

Join Eileen O'Reilly today at #GI25 to learn about new therapeutic explorations into bispecific antibodies and checkpoint inhibitors for #pancreaticcancer. #pancsm @mskcancercenter.bsky.social @ascocancer.bsky.social bit.ly/4jro4ZF 10:50 a.m. – 11 a.m. PST | Level 2, Ballroom

Dr. Vincent Picozzi is enthusiastic about the results of the PANOVA-3 trial, which uses an electricity-based technique to kill cancer cells. bit.ly/40xGxeh #PancreaticCancer #CancerSky #OncoSky #ClincalTrials

Pamrevlumab + chemo fails to improve OS and PFS in locally advanced pancreatic cancer, H/T: @lgoodbu.bsky.social

An advisory from the US Surgeon General highlights the link between alcohol consumption and #cancer, and calls for updated warning labels and more provider and patient education. More coverage here: conexiant.com/family-medic... The full advisory can be found here: www.hhs.gov/sites/defaul...

Scott Kopetz, MD, PhD, of @MDAndersonNews, reviews the BREAKWATER study on encorafenib + cetuximab ± chemotherapy for BRAF V600E–mutant metastatic colorectal cancer at ASCO GI 2025. #BreastCancer #Oncology ascopost.com/videos/2024-...